Sharon Luikart, M.D.

Dr. Luikart is the Chief of the Section of Hematology/Oncology at the Minneapolis VAMC and Professor of Medicine at the University of Minnesota.  Dr. Luikart received her M.D. from Duke University, where she also did her Internal Medicine residency. Her subspecialty training in Hematology/Oncology was at Yale University.

Dr. Luikart's clinical interest is the treatment of solid tumors, including lung cancer and melanoma. Her laboratory research interests focus on the regulation of myeloid and monocytic maturation by the micro-environment.

Selected Publications

Luikart SD, Maniglia CA, Furcht LT, McCarthy JB, Oegema TR, Jr.  A heparan sulfate-containing fraction of bone marrow stroma induces maturation of HL-60 cells in vitro.  Cancer Res 1990; 50:3781-3785.

Uhlman DL, Mooradian DL, Furcht LT, Luikart SD.  The effect of transforming growth factor-beta 1 on glycosaminoglycan production by human marrow cultures.  Exp Hematol 1990; 18:1121-1125.

Uhlman DL, Verfaillie C, Jones RB, Luikart SD.  BCNU treatment of marrow stromal monolayers reversibly alters haematopoiesis.  Br J Haematol 1991; 78:304-309.

Morrison VA, Weinshel EL, Luikart SD.  Corynebacterium JK: A new pathogen in ventriculostomy infections.  J Neurooncol 1991; 11:65-69.

Mane S, Winkelmann JC, Luikart SD.  Bone marrow extracellular matrix induces HL-60 cells to produce an autonomous differentiation factor.  Cell Growth Differ 1991; 2:637-643.

Hamdan HF, Luikart SD.  Bone marrow matrix promotes differentiation and prolongs the cell cycle of U-937 cells.  Oncol Res 1992; 4:201-207.

Ward JC, Gitlin JB, Garry DJ, Jatoi A, Luikart SD, Zelickson BD, Dahl MV, Skubitz KM.  Epidermolsis bullosa acquisita induced by GM-CSF: A role for eosinophils in treatment-related toxicity.  Br J Haematol 1992; 81:27-32.

Luikart SD, Goutsou M, Mitchell ED, van Echo DA, Modeas CR, Propert KJ, O’Donnell J, Difino S, Perry MC, Green MR.  Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer.  A report from the Cancer and Leukemia Group B.  Am J Clin Oncol 1993; 16:127-131.

Bruno E, Luikart SD, Long MW, Hoffman R.  Marrow-derived heparan sulfate proteoglycan mediates the adhesion of hematopoietic progenitor cells to cytokines.  Exp Hematol 1995; 1212-1217.

Mitchell PP, Perry MC, Luikart SD, Cirrincione CT, Van Echo DA, Herdon JE 2nd, Maurer LH, Clamon G, Green MR.  A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: A cancer and leukemia group B study.  Lung Cancer 1996; 15:215-223.

Luikart SD, Herndon JE 2nd, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR.  Phase I trial of etoposide, carboplatin and GM-CSF in extensive small-cell lung cancer: A Cancer and Leukemia Group B study (CALGB 8832).  Am J Clin Oncol 1997; 20:24-30.

Luikart S, Wahl D, Hinkel T, Masri M, Oegema T.  A fragment of alpha-actinin promotes monocytes/macrophage maturation in vitro.  Exp Hematol 1999; 27:337-344.

Masri M, Wahl D, Oegema T, Luikart S.  HL-60 cells degrade alpha-actinin to produce a fragment that promotes monocyte/macrophage maturation.  Exp Hematol 1999; 27:345-352.

Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA.  Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): Cost analysis and complications.  Leuk Res 1999; 23:953-9959.

Luikart S, Masri M, Wahl D, Hinkel T, Beck JM, Gyetko MR, Gupta P, Oegema T.  Urokinase is required for the formation of mactinin, an alpha-actinin fragment that promotes monocytes/macrophage maturation.  Biochim Biophys Acta 2002; 1591:99-107.

Luikart SD, Krug HE, Nelson RD, Hinkel T, Majeski P, Gupta P, Mahowald ML, Oegema T. Mactinin: a modulator of the monocyte response to inflammation. Arthritis Res Ther 2003; 5:R310-6.